Key Takeaway
Average weight loss on liraglutide 3.0mg is 8% of body weight per SCALE trials. Detailed data, responder analysis, and how to maximize your results.
The average weight loss on liraglutide 3.0mg is 8.0% of body weight over 56 weeks, according to the SCALE Obesity[1] and Prediabetes trial. For a 220 lb person, that translates to roughly 17.6 lbs. But averages only tell part of the story. Nearly a third of patients lost 10% or more, and some lost over 15%. Here is a deep look at the data, who does best, and how liraglutide 3.0mg compares to other options.
SCALE Trial Headline Numbers
The SCALE Obesity and Prediabetes trial remains the definitive study for liraglutide 3.0mg weight loss. It enrolled 3,731 adults with BMI of 30 or higher (or 27+ with a weight-related comorbidity), none of whom had diabetes.
| Outcome | Liraglutide 3.0mg | Placebo |
|---|---|---|
| Mean weight loss (% body weight) | 8.0% | 2.6% |
| Mean weight loss (kg) | 8.4 kg | 2.8 kg |
| Patients losing 5%+ | 63.2% | 27.1% |
| Patients losing 10%+ | 33.1% | 10.6% |
| Patients losing 15%+ | 14.4% | 3.5% |
| Mean waist circumference reduction | 8.2 cm | 3.9 cm |
Results Across Different SCALE Trials
The SCALE program included multiple trials with different patient populations. Weight loss varied by group:
View data table
| Category | Mean Body Weight Loss (%) | Detail |
|---|---|---|
| Tirzepatide | 22 | ~22% body weight at 72 wks |
| Semaglutide | 15 | ~15% body weight at 68 wks |
| Liraglutide | 8 | ~8% body weight at 56 wks |
| Retatrutide | 24 | ~24% in Phase 2 trial |
| Trial | Population | Duration | Mean Weight Loss |
|---|---|---|---|
| SCALE Obesity/Prediabetes | Non-diabetic, BMI 30+ | 56 weeks | 8.0% |
| SCALE Diabetes | Type 2 diabetes, BMI 27+ | 56 weeks | 6.0% |
| SCALE Maintenance | Pre-lost 5%+ via diet | 56 weeks | Additional 6.2% (on top of initial loss) |
| SCALE Sleep Apnea | Moderate-to-severe OSA | 32 weeks | 5.7% |
Patients with type 2 diabetes consistently lost less weight than non-diabetic patients across all GLP-1 trials. This is partly because diabetes medications (especially insulin) can promote weight gain, and partly because insulin resistance itself appears to limit weight loss response.
The Responder Spectrum
Not everyone responds equally. The 8.0% average includes both exceptional responders and modest ones. A useful way to think about it:
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →- Super responders (roughly 15% of patients): Lose 15% or more of body weight. These patients typically have strong appetite suppression, make significant dietary changes, and exercise regularly.
- Good responders (roughly 20% of patients): Lose 10 to 15%. Solid results that produce meaningful health improvements across nearly every metric.
- Moderate responders (roughly 30% of patients): Lose 5 to 10%. Cross the clinically significant threshold. Health benefits are real and documented.
- Modest responders (roughly 35% of patients): Lose less than 5%. Some still benefit metabolically even without large scale changes, but this group should discuss whether to continue, switch, or add therapies.
How Liraglutide 3.0mg Compares to Other Weight Loss Medications
| Medication | Dose | Mean Weight Loss | Trial Duration |
|---|---|---|---|
| Liraglutide (Saxenda) | 3.0mg daily | 8.0% | 56 weeks |
| Semaglutide (Wegovy) | 2.4mg weekly | 14.9% | 68 weeks |
| Tirzepatide (Zepbound) | 15mg weekly | 20.9% | 72 weeks |
| Naltrexone/bupropion (Contrave) | 32mg/360mg daily | 5.0 to 6.0% | 56 weeks |
| Orlistat (Xenical) | 120mg 3x daily | 3.0 to 4.0% | 52 weeks |
Liraglutide 3.0mg falls between the older options (orlistat, Contrave) and the newer, more potent GLP-1/GIP agonists (semaglutide, tirzepatide). It remains a strong choice for patients who need proven, well-tolerated therapy with extensive long-term data.
Maximizing Your Results at 3.0mg
SCALE trial participants received lifestyle counseling alongside the medication. Patients who most closely followed the dietary and exercise recommendations lost the most weight. To improve your results:
- Caloric target: Work with your physician or dietitian to set a deficit of 500 to 750 calories below your daily needs
- Protein intake: 1.0 to 1.2 grams per kg of ideal body weight daily to preserve muscle mass
- Exercise: 150 to 300 minutes of moderate activity per week, including 2 sessions of resistance training
- Sleep: 7 to 9 hours per night. poor sleep impairs appetite regulation and metabolic function
- Behavioral support: Patients who work with a health coach or attend counseling sessions lose more weight on average than those using medication alone
Maximizing weight loss on GLP-1 therapy
Frequently Asked Questions
Is 8% weight loss enough to improve my health?
Absolutely. An 8% weight loss improves nearly every obesity-related health marker: blood pressure drops by 5 to 10 mmHg on average, triglycerides decrease by 15 to 20%, fasting glucose and HbA1c improve, sleep apnea severity decreases, and joint pain from load-bearing stress is reduced.
Why did I lose less than 8%?
The 8% is an average, not a guarantee. Individual response is influenced by genetics, metabolic health, diet, exercise, stress, sleep, and medication adherence. If your results are below expectations, your physician can evaluate whether improving lifestyle factors, switching medications, or combination therapy might help.
Can I lose more than the trial average?
Yes. About one-third of SCALE participants lost 10% or more, and about one in seven lost 15% or more. Patients who adhere closely to dietary guidelines and maintain a regular exercise routine are the most likely to exceed the average.
Does the weight loss continue beyond 56 weeks?
Most patients plateau by 9 to 12 months. After that, the medication primarily serves to maintain the weight you have lost rather than drive further loss. The 3-year extension data confirms weight maintenance through year 3 for patients who continue.
Medical References
- Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. [PubMed | ClinicalTrials.gov | DOI]
Data-Driven Weight Loss at FormBlends
At FormBlends, we measure everything: weight, body composition, metabolic markers, and quality of life. We use this data to benchmark your progress and ensure you're getting the most from your treatment.
Curious how your results stack up? Schedule a consultation with a FormBlends physician today.
Talk to a licensed provider
Start your free assessment. A licensed provider reviews every request before anything is prescribed, and not everyone qualifies.
Start the assessment →